Treatment of primary central nervous system lymphoma

被引：9

作者：

Ekenel M. ^{[1
]}

DeAngelis L.M. ^{[1
]}

机构：

[1] Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021

来源：

Current Treatment Options in Neurology | 2007年 / 9卷 / 4期

关键词：

Overall Survival; Clin Oncol; Median Overall Survival; Radiat Oncol Biol Phys; Primary Central Nervous System Lymphoma;

D O I：

10.1007/s11940-007-0013-6

中图分类号：

学科分类号：

摘要：

Primary central nervous system lymphoma (PCNSL) is a rare form of extranodal non-Hodgkin's lymphoma that is typically confined to brain, eyes, and cerebrospinal fluid without evidence of systemic spread. The prognosis of patients with PCNSL has improved during the past decade with the introduction of high-dose methotrexate with or without whole brain radiotherapy. However, despite recent progress, results following treatment are durable in few patients, and therapy can be associated with late neurotoxicity. PCNSL is an uncommon tumor, and no phase III trial has been completed so far, leaving many questions about its optimum first-line and salvage treatments unanswered. This review summarizes the literature regarding the treatment of PCNSL in immunocompetent patients. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：271 / 282

页数：11

共 50 条

[1]

Olson J.E., Janney C.A., Rao R.D., Et al., The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: A surveillance, epidemiology, and end results analysis, Cancer, 95, pp. 1504-1510, (2002)

[2]

Panageas K.S., Elkin E.B., DeAngelis L.M., Et al., Trends in survival from primary central nervous system lymphoma, 1975-1999, Cancer, 104, pp. 2466-2472, (2005)

[3]

Abrey L.E., Yahalom J., DeAngelis L.M., Treatment for primary CNS lymphoma: The next step, J Clin Oncol, 18, pp. 3144-3150, (2000)

[4]

Nelson D.F., Martz K.L., Bonner H., Et al., Non-Hodgkin's lymphoma of the brain: Can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 83-15, Int J Radiat Oncol Biol Phys, 23, pp. 9-17, (1992)

[5]

Ferreri A., Reni M., Prognostic factors in primary central nervous system lymphomas, Hematol Oncol Clin North Am, 19, pp. 629-649, (2005)

[6]

Abrey L.E., Ben-Porat L., Panageas K.S., Et al., Primary central nervous system lymphoma: The Memorial Sloan-Kettering Cancer Center prognostic model, J Clin Oncol, 24, pp. 1-8, (2006)

[7]

Bellinzona M., Roser F., Ostertag H., Et al., Surgical removal of primary central nervous system lymphomas (PCNSL) presenting as space occupying lesions: A series of 33 cases, Eur J Surg Oncol, 31, pp. 100-105, (2005)

[8]

Weller M., Glucocorticoid treatment of primary CNS lymphoma, J Neuro-oncol, 43, pp. 237-239, (1999)

[9]

Pirotte B., Levivier M., Goldman S., Et al., Glucocorticoid induced long term remission in primary cerebral lymphoma: Case report and review of literature, J Neuro-oncol, 32, pp. 63-69, (1997)

[10]

Laack N.N., Ballman K.V., Brown P.B., Et al., Whole-brain radiotherapy and high dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-75-51, Int J Radiat Oncol Biol Phys, 65, pp. 1429-1439, (2006)

← 1 2 3 4 5 →